Q-REstrain is an advanced, personalized gene-silencing therapy that targets specific genetic sequences within cancer cells, viruses, and microorganisms to inhibit their growth or survival. By using highly precise RNA-based molecules, Q-REstrain disrupts the genetic
signals that drive disease progression at the molecular level.
Q-REstrain utilizes short, highly specific RNA molecules engineered from patient-derivedmicroRNA insights. These molecules are designed to bind directly to targeted messenger RNA (mRNA), blocking the production of proteins that allow cancer cells or pathogens to grow, divide, or evade the immune system.
This approach—known as antisense gene silencing—prevents harmful genes from being expressed. When an oligonucleotide sequence is created to be complementary to a disease- related mRNA, it neutralizes that gene’s activity, shutting down the protein pathways
responsible for tumor survival or microbial replication.
Q-REstrain is a uniquely autologous and personalized therapy created from the patient’s own biological material, making it tailored to individual genetic profiles. It supports treatment for: Solid tumors, Hematological malignancies, Viral infections (such as EBV, CMV, HPV, Hepatitis viruses, HIV etc), Lyme disease and co-infections
By blocking proteins that fuel metabolic survival pathways, Q-REstrain directly suppressesdisease activity and contributes to improved therapeutic outcomes with strong biological precision.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
“RGCC’s Oncocount test is crucial for monitoring cancer recurrence and guiding long-term treatment strategies. Its precision enables proactive management, improving patient outcomes and quality of life. A vital component of comprehensive cancer care.”
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
Positive test results confirmed the presence of CTCs within six months.
You can use any of the RGCC tests that contain CTC Count results (Example: Oncotrace, Oncotrail or Oncocount, Onconomics, Onconomics Extracts, or Onconomics Plus)
After Q-REstrain administration, the patient should be off all therapies for 7 days.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells. Once testing is complete, your sample is stored for up to six months in case further analysis is needed.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
RGCC tests like Metastat accurately detect the development of secondary tumors.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Indeed, tests are designed to reveal whether cancer cells are resistant or sensitivity to specific drugs and treatments.
Are you looking for personalized approaches to effectively target cancer cells? Supportive Oligonucleotide Therapy (Q-REstrain) is a revolutionary therapy designed to act directly on specific genes of cancer cells, inhibiting their progression. Explore the potential of personalized cancer treatment with Q-REstrain.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.